SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society, Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed on November 11, 2013.
  • 2
    Rabinovich RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206-212.
  • 3
    Janzen NK, Kim HL, Figlin RA, Belldegrun HA. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843-852.
  • 4
    Motzer RJ, Bukowki RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601-5608.
  • 5
    Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma. N Engl J Med. 2003;349:427-434.
  • 6
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
  • 7
    Escudier B, Eisen T, Stadler WM, et al;TARGET Study Group. Sorafenib in advanced renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
  • 8
    Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883-1887.
  • 9
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
  • 10
    Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-731.
  • 11
    Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936-941.
  • 12
    van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010;102:803-809.
  • 13
    Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol. 2010;194:157-165.
  • 14
    Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol. 2010;194:1470-1478.
  • 15
    Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011;59:856-862.
  • 16
    Hittinger M, Staehler M, Schramm N, et al. Course and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urol Oncol. 2012;30:695-703.
  • 17
    Schmidt N, Hess V, Zumbrunn T, et al. Choi response for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol. 2013;23:632-639.
  • 18
    Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759.
  • 19
    Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255-268.
  • 20
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
  • 21
    Zhao B, James LP, Moskowitz CS, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with nonsmall cell lung cancer. Radiology. 2009;252:263-272.
  • 22
    Nishino M, Guo M, Jackman DM, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18:54-62.
  • 23
    Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measure. 1960;20:37-46.
  • 24
    Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21:2574-2582.
  • 25
    Belton AL, Saini S, Liebermann K, Boland GW, Halpern EF. Tumour size measurement in an oncology clinical trial: comparison between off-site and on-site measurements. Clin Radiol. 2003;58:311-314.
  • 26
    Tang PA, Pond GR, Chen EX. Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Ann Oncol. 2010;21:19-25.
  • 27
    Suzuki C, Torkzad MR, Jacobsson H, et al. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol. 2010;49:509-514.
  • 28
    Skougaard K, McCullagh MJ, Nielsen D, Hendel HW, Jensen BV, Johannesen HH. Observer variability in a phase II trial-assessing consistency in RECIST application. Acta Oncol. 2012;51:774-780.
  • 29
    Muenzel D, Engels HP, Bruegel M, Kehl V, Rummeny EJ, Metz S. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiol Oncol. 2012;46:8-18.
  • 30
    Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol. 2011;29:3114-3119.
  • 31
    Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol. 1996;167:851-854.
  • 32
    Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res. 2003;9:4318-4323.
  • 33
    Nishino M, Jackman DM, Hatabu H, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010;195:W221-W228.
  • 34
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.